The chaperone Clusterin in neurodegeneration−friend or foe?
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Fibrillar protein aggregates are the pathological hallmark of a group of age‐dependent neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Aggregates of the microtubule‐associated protein Tau are observed in Alzheimer's disease and primary tauopathies. Tau pathology propagates from cell to cell in a prion‐like process that is likely subject to modulation by extracellular chaperones such as Clusterin. We recently reported that Clusterin delayed Tau fibril formation but enhanced the activity of Tau oligomers to seed aggregation of endogenous Tau in a cellular model. In contrast, Clusterin inhibited the propagation of α‐Synuclein aggregates associated with Parkinson's disease. These findings raise the possibility of a mechanistic link between Clusterin upregulation observed in Alzheimer's disease and the progression of Tau pathology. Here we review the diverse functions of Clusterin in the pathogenesis of neurodegenerative diseases, focusing on evidence that Clusterin may act either as a suppressor or enhancer of pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 2×
“[132] Clusterin is mainly expressed in the brain by astrocytes[133] (Figure 3) and its expression is positively regulated by several cytokines, including the anti-inflammatory TGF-β[134] and the pro-inflammatory IL-1β,[135] which are secreted by activated microglia.[132] Thus, inflammation is likely one of the trigger…”
BackgroundHighly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025 · cited 2×
“[14] (B) Predicted 3D-structure of Clusterin[27,28] (https://alphafold.”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 4×
“gates contribute to pathology by sequestering key cellular proteins and physically displacing organelle structures.[2,88] Chaperones, includ-”
BackgroundInfluentialZhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295 · cited 1×
“[132] Clusterin is mainly expressed in the brain by astrocytes[133] (Figure 3) and its expression is positively regulated by several cytokines, including the anti-inflammatory TGF-β[134] and the pro-inflammatory IL-1β,[135] which are secreted by activated microglia.”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“They differ in the number of N-terminal 29 amino acid inserts (0N, 1N, or 2N) and of microtubulebinding repeat domains (3Ror 4R).[94] Accumulation of hyperphosphorylated Tau in neurons facilitates the formation of fibrillar aggregates associated with AD and tauopathies (so-called neurofibrillary tangles and neuropil t…”
BackgroundStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 8×
“Interestingly, Clusterin in turn seems to directly activate microglia, which would result in a positive feedback loop contributing to maintaining the chronic state of microglial activation observed in AD.”
BackgroundInfluentialThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Research works printed but not linked: 87
- 10.1038/s41576‐018‐0011‐4 · DOI · Paper page
- 10.1002/mds.27646 · DOI · Paper page
- 10.1186/s40478‐019‐0777‐4 · DOI · Paper page
- 10.1146/annurev‐biochem‐072711‐163904 · DOI · Paper page
- 10.1038/s41467‐021‐25060‐1 · DOI · Paper page
- 10.1186/s13195‐017‐0319‐x · DOI
- 10.1515/bmc‐2015‐0026 · DOI · Paper page
- 10.3233/JAD‐2011‐111844 · DOI · Paper page
- 10.1177/0004563213503456 · DOI
- 10.1016/S0021-9258(18)32238-5 · DOI · Paper page
- 10.1083/jcb.105.6.2735 · DOI · Paper page
- 10.1159/000366365 · DOI · Paper page
- 10.1093/nar/gkaa913 · DOI · Paper page
- 10.1002/pro.5560061007 · DOI · Paper page
- 10.1038/sj.emboj.7600016 · DOI · Paper page
- 10.1096/fj.06‐7986com · DOI · Paper page
- 10.1021/bi5011249 · DOI
- 10.1186/s40478‐017‐0481‐1 · DOI · Paper page
- 10.1186/s40478‐020‐01079‐1 · DOI
- 10.1038/s41594‐018‐0057‐1 · DOI · Paper page
- 10.1016/j.celrep.2018.05.074 · DOI · Paper page
- 10.1021/bi010135x · DOI · Paper page
- 10.1111/j.1432‐1033.1994.tb18807.x · DOI · Paper page
- 10.1016/j.bone.2018.02.018 · DOI
- 10.1016/j.bbcan.2020.188500 · DOI
- 10.1172/JCI113531 · DOI · Paper page
- 10.1038/s41467‐021‐26366‐w · DOI · Paper page
- 10.1016/S0021-9258(19)38290-0 · DOI · Paper page
- Suzuki T., 2002, Predominant apolipoprotein J exists as lipid‐poor mixtures in cerebrospinal fluid, Annals of Clinical and Laboratory Science, 32, 369
- 10.1186/s13195‐019‐0498‐8 · DOI · Paper page
- 10.1111/j.1600‐0854.2007.00549.x · DOI · Paper page
- 10.1074/jbc.M111.252957 · DOI
- 10.1016/j.tibs.2021.01.005 · DOI
- 10.3389/fnins.2018.00504 · DOI · Paper page
- 10.1042/BJ20051190 · DOI · Paper page
- 10.2174/1389203718666170918155247 · DOI
- 10.1126/sciadv.aau3112 · DOI · Paper page
- 10.1038/nsmb.2191 · DOI · Paper page
- 10.1074/jbc.M115.689539 · DOI · Paper page
- 10.1186/s13024‐020‐00416‐1 · DOI · Paper page
- 10.1186/s12868‐018‐0402‐7 · DOI
- 10.1186/s13024‐021‐00426‐7 · DOI · Paper page
- 10.1073/pnas.1701137114 · DOI · Paper page
- 10.1111/bpa.12660 · DOI · Paper page
- 10.1021/ja3103567 · DOI · Paper page
- 10.1073/pnas.95.11.6448 · DOI · Paper page
- 10.1093/brain/awaa223 · DOI · Paper page
- 10.1038/ng.439 · DOI · Paper page
- 10.1186/s13024‐015‐0024‐9 · DOI · Paper page
- 10.1038/tp.2011.17 · DOI · Paper page
- 10.1371/journal.pone.0095152 · DOI · Paper page
- 10.1016/j.exer.2014.07.005 · DOI
- 10.1093/hmg/ddx329 · DOI
- 10.1212/WNL.0b013e3182605801 · DOI · Paper page
- 10.1038/srep26027 · DOI · Paper page
- 10.1016/j.neuropsychologia.2013.12.020 · DOI · Paper page
- 10.1016/j.jpsychires.2020.07.015 · DOI
- 10.1016/j.jalz.2014.10.012 · DOI · Paper page
- 10.2174/1567205013666160703180531 · DOI
- 10.1038/s41591‐018‐0206‐4 · DOI · Paper page
- 10.1016/j.neurobiolaging.2019.10.025 · DOI · Paper page
- 10.1371/journal.pone.0190478 · DOI
- 10.1210/en.2013‐1870 · DOI
- 10.1039/c4cp05563b · DOI · Paper page
- 10.1038/ncomms10948 · DOI · Paper page
- 10.1007/s12551‐017‐0289‐z · DOI
- 10.1093/emboj/16.7.1501 · DOI · Paper page
- 10.1038/ncomms13673 · DOI · Paper page
- 10.1016/j.tibs.2021.12.009 · DOI
- 10.15252/embj.201593489 · DOI · Paper page
- Wu S. Sirkis D. W. &Schekman R.(2022). Unconventional secretion of α‐synuclein mediated by palmitoylated DNAJC5 oligomers.bioRxiv. 2022.027.477991.https://doi.org/10.1101/2022.01.27.477991 · doi:10.1101/2022.01.27.477991
- 10.1371/journal.pone.0103187 · DOI · Paper page
- 10.1016/j.bbih.2021.100242 · DOI · Paper page
- 10.3389/fncel.2019.00403 · DOI · Paper page
- 10.1007/s00401‐017‐1722‐x · DOI · Paper page
- 10.1007/s00018‐011‐0684‐8 · DOI · Paper page
- 10.1083/jcb.201911126 · DOI
- 10.1007/s00702‐010‐0462‐z · DOI
- 10.1093/hmg/ddw188 · DOI
- 10.1038/ncomms2896 · DOI
- 10.1006/excr.2001.5358 · DOI
- 10.1242/jcs.228213 · DOI · Paper page
- 10.1016/0165‐5728(94)00194‐s · DOI
- 10.1006/mcne.1994.1027 · DOI
- 10.1146/annurev‐neuro‐061010‐113810 · DOI · Paper page
- 10.1186/s12974‐020‐02024‐8 · DOI · Paper page
- 10.1093/bioinformatics/15.4.305 · DOI · Paper page
Cited by
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
The selenoprotein methionine sulfoxide reductase B1 (MSRB1)
Tarrago, L., Kaya, A., Kim, H.-Y., Manta, B., Lee, B.-C., & Gladyshev, V. N. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.08.043 · Cited by 39
The Role of Genetic, Environmental, and Dietary Factors in Alzheimer’s Disease: A Narrative Review
Mertaş, B., & Boşgelmez, İ. İ. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031222 · Cited by 35
Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred
Cochran, J. N., Acosta‐Uribe, J., Esposito, B. T., Madrigal, L., Aguillón, D., Giraldo, M. M., Taylor, J. W., Bradley, J., Fulton‐Howard, B., Andrews, S. J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13021 · Cited by 21
Metadata
- Authors
- Yuste‐Checa, P., Bracher, A., & Hartl, F. U.
- Venue
- BioEssays
- Publisher
- Wiley
- Published
- 2022-05-06
- Volume
- 44
- Issue
- 7
- Pages
- e2100287-e2100287
- ISSN
- 0265-9247 (ISSN-L)
- 1521-1878
- OpenAlex
- W4229006902
- Cited by
- 37
- References
- 53
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.